S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

from OncLive® On Air · host OncLive® On Air

Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Episode metadata supplied by the publisher feed · Published Jan 4, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

0:00 14:01

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 14 minutes long.

When was this OncLive® On Air episode published?

This episode was published on January 4, 2024.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!